Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) ...

For the first time, University of Hawaiʻi at Mānoa researchers have studied how work, volunteering and leisure activities ...

Apolipoprotein A-I mimetic peptides are amphipathic alpha-helix peptides that display similar functions to apolipoprotein A-I. Preclinical and clinical studies have demonstrated the safety and ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...

High cholesterol levels can pose significant risks to health, including affecting memory. Research highlights a link between ...

She corrects the widespread misconception, claiming that eradicating fat to reduce cholesterol is "nonsense." Contrary to ...

The study, published in Food Frontiers, concluded that plant-based meat alternatives are likely to be safe when part of a ...

Background Aortic stenosis is a degenerative condition with high mortality in its severe stages and no preventive treatment.

Maze Therapeutics Inc. has divulged apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic retinopathy, ...

Cholesterol is a fatty substances which collects in our blood vessels, and is caused by things like diet, exercise, and ...

Prolonged rapid eye movement latency may be a potential marker for Alzheimer disease and Alzheimer disease and related dementias.